Dr. Guoming Shi 施国明
Chief Physician, Associate Professor
Department of Hepatobiliary Oncology and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Precision surgery for liver cancer, intrahepatic cholangiocarcinoma, complex hilar cholangiocarcinoma, large liver tumors, hepatic hemangiomas, metastatic liver cancer, laparoscopic liver tumor surgery, liver transplantation, and comprehensive cholangiocarcinoma treatment.
Dr. Shi holds an MD and completed a one-year fellowship at a Harvard Medical School affiliate hospital. As Chief Physician and doctoral supervisor, Dr. Shi has performed over 1,500 liver resections and 300 liver transplants, including complex procedures. The team leads research on novel intrahepatic cholangiocarcinoma treatments. Dr. Shi has published over 30 SCI papers and received the 2015 Ministry of Education Natural Science Award (First Class) and the 2013 Meiji Life Science Award (Outstanding).
Professional roles
- Member, Liver Metastasis Committee, China Anti-Cancer Association
- Youth Committee Member, Oncology Branch, Chinese Medical Association
Name order: in Chinese the family name comes first (Shi Guoming). Papers usually list the name as Guoming Shi or Shi G.
Selected publications
126 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Gut, 2026 (senior author): Norepinephrine promotes tumour cell aggressiveness and NK cell ferroptosis via ADRB2 in intrahepatic cholangiocarcinoma with perineural invasion. PubMed 42009561
- N Engl J Med, 2026 (first author): Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma. PubMed 41780001
- Cancer Lett, 2025 (senior author): A noninvasive and highly efficient epigenetic predictive model for efficacy of the GOLP regimen in patients with intrahepatic cholangiocarcinoma. PubMed 40651656
- Lancet Oncol, 2025 (first author): Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study. PubMed 40889502
- Signal Transduct Target Ther, 2025 (first author): First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study. PubMed 40835595
- Mol Cancer, 2024 (senior author): Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. PubMed 38424621
- Signal Transduct Target Ther, 2023 (first author): Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. PubMed 36928584
- Hepatol Int, 2023 (senior author): The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion. PubMed 36418844
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion